AstraZeneca to Invest $1.5 Billion in Singapore Cancer Drug Plant

The facility will be the company's first end-to-end site for producing next-generation antibody-drug conjugates, targeting precision cancer therapies.

Construction will begin by the end of 2024, with operations expected to start in 2029.
The plant will produce antibody-drug conjugates (ADCs) that target cancer cells while sparing healthy ones.
This investment is supported by Singapore's Economic Development Board.
The facility is designed to have zero carbon emissions from its first day of operation.
AstraZeneca aims to enhance its supply chain and reduce reliance on China.